- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Targeted Drug Side Effects Add to Cancer Costs
The average cost of treating each cancer patient who came into a dermatology clinic with skin, hair and nail complaints was almost $2,000, researchers reported this week. That included expenses related to doctors' appointments, dermatology medications and lab tests.
Some patients with skin problems may have to delay or alter their treatment regimen if side effects are too severe, researchers said.
"Dermatologic side effects including skin irritation and dry skin are the two topmost concerns that patients have that they did not expect during therapy," said Dr. Mario Lacouture from Memorial Sloan-Kettering Center Center in New York, who worked on the study.
"They were prepared to get hair loss, they were prepared to get some nausea and diarrhea, but they weren't expecting to get all these skin issues," he told Reuters Health.
Read more at: http://www.reuters.com/article/2011/12/21/us-targeted-drug-side-effects-idUSTRE7BK25020111221
Source: Reuters
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
